Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BIIB104 PK and Safety in Healthy Japanese and Non-Japanese Participants
NCT05148481Phase 1Completed
- Sponsor
- Biogen
- Start
- Nov 2021
- Primary completion
- Jan 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of pesampator in schizophrenia (3 arms), sponsored by Biogen. Primary endpoints: Maximum Observed Concentration, Time to Reach Maximum Observed Concentration and 9 more. Started Nov 2021; status: completed.
02
Drugs
pesampator
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT05148481.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05148481.